Welcome to our dedicated page for Immunome SEC filings (Ticker: IMNM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immunome, Inc. filings document the company’s targeted oncology business, public-company governance, capital structure, and material event disclosures. Its 8-K reports cover operating results, business updates, clinical and regulatory communications for programs such as varegacestat and IM-1021, investor presentations, and equity financing activity involving its common stock.
Proxy materials describe board matters, stockholder voting items, executive compensation, equity plans, and governance practices. The filing record also reflects Nasdaq-listed common stock, stock-based compensation arrangements, and formal disclosures tied to the development of antibody-drug conjugates, gamma secretase inhibition, and FAP-targeted radiotherapy within Immunome’s oncology pipeline.
Immunome Inc.’s Chief Business Officer, Kinney Horn, received equity compensation awards. On July 23, 2026, Horn was granted 31,250 shares of common stock underlying RSUs and 62,500 employee stock options with a $22.01 exercise price, vesting over time subject to continuous service, with options expiring July 22, 2036.
Immunome Inc. reported equity awards to Chief Technical Officer Philip Tsai on July 23, 2026. Tsai received 76,500 stock options at a $22.01 exercise price expiring in 2036 and 38,250 RSUs, all vesting over time contingent on his continuous service, bringing reported direct holdings to 81,550 common shares/RSUs.
Immunome Inc. reported equity awards to its Chief Legal Officer and General Counsel, Sandra G. Stoneman. On July 23, 2026 she received stock options for 76,500 shares at a $22.01 exercise price, expiring July 22, 2036, plus 38,250 RSUs. The RSUs vest 25% annually on each grant-date anniversary, and the options vest 25% on July 23, 2027 with the balance vesting monthly over three years, in each case subject to continued service. Following the RSU award she directly holds 43,805 shares or RSUs of common stock.
Higgins Jack reported acquisition or exercise transactions in this Form 4 filing.
Immunome Inc. granted Chief Scientific Officer Jack Higgins 76,500 employee stock options to buy Common Stock at $22.01 per share, expiring in 2036, and 38,250 RSU-based Common Stock awards on 2026-07-23. Both the options and RSUs vest over time, subject to continuous service, and Higgins also reports indirect custodial holdings of 1,000 shares for each of three children, for which beneficial ownership is disclaimed.
Immunome Inc. Chief Financial Officer Max Rosett received equity awards of 94,500 employee stock options and 47,250 restricted stock units on July 23, 2026.
The options have a $22.01 exercise price, expire July 22, 2036, and vest 25% on July 23, 2027 with the remainder vesting monthly. The RSUs vest 25% annually on each grant anniversary; after the RSU grant he held 101,287 common shares directly and 94,500 options.
Immunome Inc. granted Chief Medical Officer Robert Lechleider 54,000 RSUs and an employee stock option for 108,000 shares at a $22.01 exercise price on 2026-07-23. The RSUs vest 25% annually, while the options vest 25% on July 23, 2027 and monthly thereafter. After these awards he directly holds 69,805 common shares and 108,000 options.
Immunome Inc. granted equity awards to President and CEO Clay B. Siegall on July 23, 2026. He received 180,000 RSUs, with 25% vesting on each anniversary of the grant date, and 360,000 stock options with a $22.01 exercise price, 25% vesting on July 23, 2027 and the remainder in equal monthly installments thereafter, all subject to continued service. Following the RSU grant, he directly holds 870,704 common shares, in addition to the newly granted options.
Immunome Inc. chief business officer Horn Kinney reported an option exercise and share sale. On the same day, Kinney exercised employee stock options to acquire 1,092 shares of common stock at $12.92 per share and sold 1,092 shares at $25.00 per share in an open-market transaction.
The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on March 30, 2026. Following these transactions, Kinney reported no directly held common shares and 128,908 employee stock options remaining, exercisable at $12.92 and expiring on August 8, 2034.
Immunome Inc. director Isaac Barchas reported that an entity associated with him, AMBHMC II LLC, sold a total of 100,000 shares of Immunome common stock in open-market transactions under a pre-arranged Rule 10b5-1 trading plan adopted on March 31, 2026.
The sales occurred on July 6 and July 7, 2026, at weighted average prices of about $24.11 and $24.20 per share across specified price ranges. After these transactions, filings show 108,504 shares held indirectly and 103,259 shares held directly. Barchas disclaims beneficial ownership of the LLC-held shares beyond any pecuniary interest.
Robert Lechleider, Chief Medical Officer of Immunome, exercised stock options for 55,000 shares of common stock at $8.73 per share on July 2, 2026, then sold 55,000 shares in three tranches at weighted average prices of $21.95, $22.76 and $23.44 per share under a Rule 10b5-1 trading plan adopted on March 26, 2026. Following these transactions, he directly holds 15,805 shares of common stock.